Vaxart, Inc. (NASDAQ:VXRT – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.41 and traded as low as $0.35. Vaxart shares last traded at $0.3626, with a volume of 406,853 shares changing hands.
Vaxart Trading Down 2.5%
The firm has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $0.41. The stock has a market cap of $83.02 million, a price-to-earnings ratio of -1.34 and a beta of 1.32.
Institutional Investors Weigh In On Vaxart
A number of institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. increased its holdings in Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares during the period. Invesco Ltd. boosted its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 70,568 shares in the last quarter. Creative Planning acquired a new stake in shares of Vaxart during the 2nd quarter valued at about $33,000. Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart during the 1st quarter valued at about $31,000. Finally, Virtu Financial LLC bought a new stake in Vaxart in the first quarter valued at about $56,000. Institutional investors and hedge funds own 18.05% of the company’s stock.
Vaxart Company Profile
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
See Also
- Five stocks we like better than Vaxart
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Rare Earth Stocks: The Truce That Isn’t a Truce
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- How to buy stock: A step-by-step guide for beginners
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
